Progress has been made from drug re-purposing efforts. Perhaps, the "poster child" of a re-purposed drug for oncology treatment is the good old aspirin. Studies show that daily aspirin enhances post-cancer treatment survival by 20%. According to a recent report by scientists at Oregon Health and Science University, aspirin may slow down the growth and migration of certain types of colon and pancreatic cancers.
Another study conducted by a research group at the Mayo Clinic reports that a daily dose of 600mg (a high dose) for two years led to an almost 60% reduction in developing colorectal cancer (CRC) in men and women who were susceptible to hereditary non-polyposis colon cancer (also known as Lynch syndrome), compared to a placebo control group.
A quick note on aspirin and disorder-associated dosages:
- For cardiovascular prevention: 75 - 235 mg/day
- For anti-inflammation: 1,000 mg/day
- For diminishing cancer reoccurrence (as described above): 600 mg/day
